IMNN · Imunon, Inc. · Investor Relations

Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON's Commitment to Its Core Strategy: Executing the Pivotal Phase 3 OVATION 3 Trial of IMNN-001

LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026

Unique investment vehicle provides efficient access to equity capital Outstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”),

2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis

Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001's

Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001 in new indications and combination regimens IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration LAWRENCEVILLE, N.J., Sept.

Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated

Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones A patient treated with IMNN-001 will share firsthand perspective on her treatment journey and life following participation in the

IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by the first half of 2029, supported

LAWRENCEVILLE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, August 11, 2026 to discuss financial results

Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company’s large, randomized Phase II study, OVATION 2 Strong enrollment demonstrates the confidence of principal investigators from prestigious cancer

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism First-of-its-kind meeting spotlights IMNN-001 as one of the novel technologies shaping the future of cancer drug discovery and development